Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Dani Ran Castillo
Observed names:
D.R. Castillo,
Dan Ran Castillo,
Dani Ran Castillo,
Dani Castillo,
Dani R. Castillo
Institutions:
City Of Hope National Medical Center,
Loma Linda University,
City of Hope
Observed institutions:
Loma Linda University Medical Center,
City Of Hope National Medical Center,
Loma Linda University,
Englewood Hospital and Medical Center,
Loma Linda University Health Care,
City of Hope,
Caris Life Sciences (United States)
show all 7
ORCID:
0000-0002-5762-6683
Observed ORCID:
0000-0002-5762-6683
OpenAlex ID:
A5032537689
The emerging role of blood-based biomarkers in early detection of colorectal cancer: A systematic review
2024
·
Faris Shweikeh
, Yuhao Zeng
, et al.
·
Cancer Treatment and Research Communications
·
31
Targeting the Tumor Microenvironment in Acute Myeloid Leukemia: The Future of Immunotherapy and Natural Products
2022
·
Christopher Hino
, Bryan Pham
, et al.
·
Biomedicines
·
29
PDF
Survival and Treatment Patterns in Stage II to III Esophageal Cancer
2024
·
Won Jin Jeon
, Daniel Park
, et al.
·
JAMA Network Open
·
25
Advancing Esophageal Cancer Treatment: Immunotherapy in Neoadjuvant and Adjuvant Settings
2024
·
Daniel Park
, Won Jin Jeon
, et al.
·
Cancers
·
23
PDF
HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors
2025
·
Thomas Powles
, Aarti Bhatia
, et al.
·
Future Oncology
·
16
PDF
Partial response to venetoclax and ruxolitinib combination in a case of refractory T-prolymphocytic leukemia
2023
·
Joel Brothers
, Dan Ran Castillo
, et al.
·
Hematology
·
13
PDF
Comprehensive Review: Unveiling the Pro-Oncogenic Roles of IL-1ß and PD-1/PD-L1 in NSCLC Development and Targeting Their Pathways for Clinical Management
2023
·
Dan Ran Castillo
, Won Jin Jeon
, et al.
·
International Journal of Molecular Sciences
·
11
PDF
PARP inhibitors in gastric cancer: unlocking precision oncology
2025
·
Derek Tai
, Vitor Goes
, et al.
·
The Oncologist
·
8
Multi-analyte liquid biopsy approaches for early detection of esophageal cancer: the expanding role of ctDNA
2025
·
Derek Tai
, Kareem Latif
, et al.
·
Frontiers in Oncology
·
8
PDF
690TiP HERTHENA-PanTumor01: A global phase II trial of HER3-DXd in metastatic solid tumors
2024
·
T.B. Powles
, A.K. Bhatia
, et al.
·
Annals of Oncology
·
8
PDF
Outcomes of the Pregnancies with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era and Literature Review
2022
·
Dan Ran Castillo
, Daniel Park
, et al.
·
Hematology Reports
·
8
PDF
Phase 1/2 study of spevatamig (PT886) in combination with gemcitabine plus nab-paclitaxel (GnP) in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).
2026
·
Anwaar Saeed
, Michael J. Overman
, et al.
·
Journal of Clinical Oncology
·
7
LIF / LIFR Signaling in Gastric Cancer: A Double‐Edged Sword in Tumor Progression and Therapeutic Resistance
2025
·
Daniel Park
, Kyung‐Il Kim
, et al.
·
Cancer Medicine
·
6
PDF
Successful Treatment of Autoimmune Hemolytic Anemia Concomitant with Proliferation of Epstein-Barr Virus in a Post-Heart Transplant Patient
2022
·
Dan Ran Castillo
, Parthiv Sheth
, et al.
·
Hematology Reports
·
6
PDF
SMARCA4 Deficient Gastric Carcinoma With Squamous Differentiation in a Young Patient With Aggressive Clinical Course
2024
·
Sunayana Misra
, Wai Szeto
, et al.
·
International Journal of Surgical Pathology
·
5
Portal vein thrombosis as the presenting manifestation of JAK2 positive myeloproliferative neoplasm
2023
·
Won Jin Jeon
, Akhil Mehta
, et al.
·
The American Journal of the Medical Sciences
·
5
Late renal toxicity in patient with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib: A case report and literature review
2022
·
Bryan Pham
, Sue Min Kwon
, et al.
·
Journal of Oncology Pharmacy Practice
·
5
Spevatamig (PT886), a claudin 18.2 (CLDN18.2)/CD47 bispecific antibody, in combination with gemcitabine plus nab-paclitaxel (GnP) in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).
2026
·
Anwaar Saeed
, Rui-Hua Xu
, et al.
·
Journal of Clinical Oncology
·
4
Microbiome Signatures in Advanced Gastric Cancer: Emerging Biomarkers for Risk Stratification, Therapy Guidance, and Prognostic Insight
2026
·
Kyung-il John Kim
, Hannah Zhong
, et al.
·
International Journal of Molecular Sciences
·
4
PDF
Distinct clinicopathological and survival profiles of CLDN18.2 and PD-L1 expression in advanced gastric cancer and gastroesophageal junction adenocarcinoma
2025
·
D.R. Castillo
, M. Guo
, et al.
·
ESMO Gastrointestinal Oncology
·
4
Association of Claudin18.2 expression, PD-L1, and prognostic implications in gastric and gastroesophageal junction cancers.
2025
·
Dani Ran Castillo
, Mengni Guo
, et al.
·
Journal of Clinical Oncology
·
4
PDF
Biomarker-driven therapeutic strategies in advanced gastric cancer: a case series of curative responses
2025
·
Daniel Park
, Lu Pu
, et al.
·
Journal of Gastrointestinal Oncology
·
4
Perianal basosquamous carcinoma treated with radiation therapy, a case report
2023
·
Stephanie Y. Kwan
, Dani Ran Castillo
, et al.
·
Journal of Gastrointestinal Oncology
·
4
PDF
Primary gastric squamous cell carcinoma in a young adult with immunotherapy complications: a case report
2025
·
Yu-Han Chen
, Bowon Joung
, et al.
·
Journal of Gastrointestinal Oncology
·
3
HERTHENA-PanTumor01: A global, multicohort, phase 2 trial of HER3-DXd in relapsed/refractory metastatic solid tumors.
2024
·
Aarti K. Bhatia
, Hidetoshi Hayashi
, et al.
·
Journal of Clinical Oncology
·
3
PDF
Show more works
View as search
Works count:
71
Citation count:
269
H-index:
8
I10-index:
7
Year
Topic
Type